The hardest hit areas of the HIV/AIDS epidemic are often rural areas that struggle to provide the testing and treatment options offered by medical facilities in larger, more populated areas. And clinics are sometimes hundreds of miles from patients in need.“The needs are really where...
You are here
DIAGNOSTICS FOR THE REAL WORLD LIMITED
Company Information
Information
UEI: C4HLGZ5MXBH7
# of Employees: 20
Ownership Information
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
Development of a simple and robust point-of-care test for detection of Hepatitis C RNA from finger prick whole blood in resource-limited settings
Amount: $143,627.00Phase I ApplicationDevelopment of a simple and robust point of care test for detection of Hepatitis C RNA fromfinger prick whole blood in resource limited settingsProject Summary Diagnostics for the R ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Commercial Readiness for SAMBA HIV Whole Blood Semi Quantitative Test for Resource Limited Settings
Amount: $907,877.00Diagnostics for the Real World Ltd Commercialization Readiness Pilot Application SAMBA HIV Whole Blood Semi Quantitative Test for Resource Limited Settings Abstract DRW is requesting Technical As ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Development of two simple and robust point-of-care assays for detection and therapy monitoring of hepatitis B in resource-limited settings
Amount: $1,358,849.00SBIR Direct Phase II Application Development of two simple and robust point of care assays for detection and therapy monitoring ofhepatitis B in resource limited settings Project Summary Abstract Diag ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Commercial Readiness for SAMBA HIV-1 Whole Blood Semi-Quantitative Test for Resource Limited Settings
Amount: $2,730,147.00Diagnostics for the Real WorldLtdCommercialization Readiness Pilot Application SAMBA HIVWhole Blood Semi Quantitative Test for Resource Limited Settings Abstract DRW is requesting Technical Assistance ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
SAMBA HIV-1 Semi-quantitative whole blood test for resource limited settings
Amount: $951,508.00DESCRIPTION provided by applicant The ultimate aim of this project is to develop diagnostic platform for viral load monitoring using whole blood samples of HIV infected patients in point of care ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
SAMBA HIV-1 Semi-quantitative Test for resource limited settings
Amount: $1,365,113.00DESCRIPTION provided by applicant SAMBA HIV Semi quantitative Test for resource limited settings Project Abstract The ultimate aim of this project is to develop a CE marked and or FDA approved d ...
SBIRPhase II2014Department of Health and Human Services National Institutes of Health -
SAMBA HIV-1 Semi-quantitative Test for resource limited settings
Amount: $581,764.00DESCRIPTION (provided by applicant): The ultimate aim of this project is to develop a CE-marked and/or FDA-approved diagnostic platform for viral load monitoring of HIV-1 infected patients in point-of ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
DRW HIV-Ab/HCV-Ab/HBsAg Triplex Rapid Test Submission for FDA-PMA Approval
Amount: $1,911,380.00DESCRIPTION (provided by applicant): Confidential information: patent application in process. Diagnostics for the Real World, Ltd. (DRW) aims to market a high-performance triplex rapid test (DRW HIV- ...
SBIRPhase II2010Department of Health and Human Services National Institutes of Health -
DRW HIV-Ab/HBsAg Duplex Rapid Test submission for FDA-PMA approval
Amount: $1,782,780.00DESCRIPTION (provided by applicant): Confidential information: Patent application in process. Diagnostics for the Real World, Ltd. (DRW) aims to market a high-performance duplex rapid test (DRW HIV-Ab ...
SBIRPhase II2008Department of Health and Human Services National Institutes of Health -
Preclinical and clinical studies of an HBV rapid test for FDA Pre-market approval
Amount: $964,487.00DESCRIPTION (provided by applicant): Diagnostics for the Real World, Ltd. (DRW) aims to market a high-performance rapid test for hepatitis B virus (DRW HBsAg Rapid Test) that will be useful as a diagn ...
SBIRPhase II2007Department of Health and Human Services National Institutes of Health
